Pipeline
Fueled by its proprietary auto-palmitoylation platform, Tasca is building a pipeline of innovative drug discovery programs across multiple cancer indications.
CP-383 FIRST IN CLASS INHIBITOR MULTI-CANCER INDICATIONS
PROGRAM 2
CANCER INDICATIONS
PROGRAM 3
CANCER INDICATIONS
DISCOVERY
LO
IND-ENABLING
PHASE 1
Pipeline
Fueled by its proprietary auto-palmitoylation platform, Tasca is building a pipeline of innovative drug discovery programs across multiple cancer indications.